Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00178230 · ClinicalTrials.gov registry record

Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity

A clinical trial of Lung Neoplasms, sponsored by University of Rochester.

Completed
Registry status
82
Enrollment target
1
Study location

NCT00178230: Completed study of Lung Neoplasms, sponsored by University of Rochester.

NCT00178230 is a study of Lung Neoplasms that has completed, run by University of Rochester. The registered enrollment target is 82 participants, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00178230, a study of Lung Neoplasms, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
82 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted by the University of Rochester Cancer Center to determine the levels of cytokines in the blood, and to determine if blood levels of these cytokines are related to the side effects of radiation therapy combined with other treatments.

Conditions Studied

Study Locations (1)

New York

  • University of Rochester, Dept. Radiation Oncology - Rochester

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 1996-03-15
Est. Completion 2013-11-25
University of Rochester

636 total trials

What the finished NCT00178230 record still lists

NCT00178230 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Lung Neoplasms appearing as the primary indexed condition, and to 0 interventions.

NCT00178230 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00178230 about?

NCT00178230 is a clinical study titled "Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity". This study is being conducted by the University of Rochester Cancer Center to determine the levels of cytokines in the blood, and to determine if blood levels of these cytokines are related to the side effects of radiation therapy combined with other treatments.

What is the current status of trial NCT00178230?

This trial is currently completed. The enrollment target is 82 participants. The study started on 1996-03-15. Estimated completion is 2013-11-25.

What conditions does trial NCT00178230 study?

This clinical trial studies the following conditions: Lung Neoplasms.

Who is sponsoring clinical trial NCT00178230?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00178230 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00178230's enrollment target sits among peer trials

82 11th of 22 higher than 12 of 22 other Lung Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03319901 · 82 participants · Phase 1

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

  • NCT03493425 · 82 participants · Phase 2

    Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

  • NCT04105270 · 82 participants · Phase 2

    RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

  • NCT04428658 · 82 participants · NA

    Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00178230, the US trial registry maintained by the National Library of Medicine. NCT00178230 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.